We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
argenex SE (ARGX - Free Report) shares ended the last trading session 5.8% higher at $891.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7% gain over the past four weeks.
argenx SE share price gain can likely be attributed to the growing investor confidence in its blockbuster drug, Vyvgart. The FDA approved the expanded use of Vyvgart and Vyvgart Hytrulo,making them the first and only treatments approved for all adult patients with generalized myasthenia gravis (gMG), regardless of antibody status. The drug generated $1.3 billion in global net product sales in the first quarter of 2026, up 63% year over year. Beyond approved indications, the company is pursuing significant label expansion opportunities in adults with ocular myasthenia gravis (oMG), pediatric gMG and several additional autoimmune diseases.
This company is expected to post quarterly earnings of $6.27 per share in its upcoming report, which represents a year-over-year change of +67.7%. Revenues are expected to be $1.45 billion, up 49.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Argenx, the consensus EPS estimate for the quarter has been revised 8.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ARGX going forward to see if this recent jump can turn into more strength down the road.
Argenx is part of the Zacks Medical - Biomedical and Genetics industry. Bristol Myers Squibb (BMY - Free Report) , another stock in the same industry, closed the last trading session 1.2% higher at $57.27. BMY has returned 0.6% in the past month.
For Bristol Myers, the consensus EPS estimate for the upcoming report has changed -0.7% over the past month to $1.61. This represents a change of +10.3% from what the company reported a year ago. Bristol Myers currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
argenex SE (ARGX - Free Report) shares ended the last trading session 5.8% higher at $891.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7% gain over the past four weeks.
argenx SE share price gain can likely be attributed to the growing investor confidence in its blockbuster drug, Vyvgart. The FDA approved the expanded use of Vyvgart and Vyvgart Hytrulo,making them the first and only treatments approved for all adult patients with generalized myasthenia gravis (gMG), regardless of antibody status. The drug generated $1.3 billion in global net product sales in the first quarter of 2026, up 63% year over year. Beyond approved indications, the company is pursuing significant label expansion opportunities in adults with ocular myasthenia gravis (oMG), pediatric gMG and several additional autoimmune diseases.
This company is expected to post quarterly earnings of $6.27 per share in its upcoming report, which represents a year-over-year change of +67.7%. Revenues are expected to be $1.45 billion, up 49.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Argenx, the consensus EPS estimate for the quarter has been revised 8.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ARGX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Argenx is part of the Zacks Medical - Biomedical and Genetics industry. Bristol Myers Squibb (BMY - Free Report) , another stock in the same industry, closed the last trading session 1.2% higher at $57.27. BMY has returned 0.6% in the past month.
For Bristol Myers, the consensus EPS estimate for the upcoming report has changed -0.7% over the past month to $1.61. This represents a change of +10.3% from what the company reported a year ago. Bristol Myers currently has a Zacks Rank of #3 (Hold).